Endothelium-Dependent Effects of Statins
Top Cited Papers
- 1 May 2003
- journal article
- review article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 23 (5) , 729-736
- https://doi.org/10.1161/01.atv.0000063385.12476.a7
Abstract
The vascular endothelium is a dynamic endocrine organ that regulates contractile, secretory, and mitogenic activities in the vessel wall and hemostatic processes within the vascular lumen. Risk factors for cardiovascular disease, such as cigarette smoking, hypertension, and elevated serum lipid levels, impair endothelial function and lead to the development of atherosclerotic vessels. Recent studies suggest that statins reduce cardiovascular events in part by improving endothelial function. Statins reduce plasma cholesterol levels, thereby decreasing the uptake of modified lipoproteins by vascular wall cells. There is increasing evidence, however, that statins may also exert effects beyond cholesterol lowering. Indeed, many of these cholesterol-independent or “pleiotropic” vascular effects of statins appear to involve restoring or improving endothelial function through increasing the bioavailability of nitric oxide, promoting re-endothelialization, reducing oxidative stress, and inhibiting inflammatory responses. Thus, the endothelium-dependent effects of statins are thought to contribute to many of the beneficial effects of statin therapy in cardiovascular disease.Keywords
This publication has 81 references indexed in Scilit:
- Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjectsBritish Journal of Clinical Pharmacology, 2002
- Neuroprotection mediated by changes in the endothelial actin cytoskeletonJournal of Clinical Investigation, 2000
- Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.Journal of Clinical Investigation, 1998
- Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell lineInternational Journal of Immunopharmacology, 1996
- Hyperlipidaemia, hypertension, and coronary heart diseaseThe Lancet, 1995
- The acute phase responseImmunology Today, 1994
- Lovastatin but not enalapril reduces glomerular injury in Dahl salt-sensitive rats.Hypertension, 1992
- The Pathogenesis of Coronary Artery Disease and the Acute Coronary SyndromesNew England Journal of Medicine, 1992
- Modified low density lipoproteins activate human macrophages to secrete immunoreactive endothelinFEBS Letters, 1991
- Regulation of the mevalonate pathwayNature, 1990